238. ビタミンD抵抗性くる病/骨軟化症
[臨床試験数:1,薬物数:1(DrugBank:0),標的遺伝子数:0,標的パスウェイ数:0]

Searched query = "Vitamin D-resistant rickets", "Vitamin D-resistant osteomalacia", "FGF23-related hypophosphatemic disease", "FGF23-related hypophosphatemia", "VDRR", "VDRO"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-101332
01/9/201002/11/2010Therapeutic use of Z-521Therapeutic use of oral sodium phosphate (Z-521) in primary hypophosphatemic rickets (familial rickets, X-linked hypophosphatemia, vitamin D-resistant rickets) primary hypophosphatemic ricketsIntervention name : Z-521
Dosage And administration of the intervention : 300-3000mg inorganic phosphorus is orally administered in 3 or 4 times per day
Zeria Pharmaceutical Co., Ltd.NULL114BOTH10Phase 3NULL